Artesunate relieves subchondral bone osteoclast-mediated
osteoarthritis pain

doi:10.3969/j.issn.2095-4344.2672

Abstract

Abstract:

BACKGROUND: Studies have shown that osteoclasts induce aberrant in growth of sensory nerves into the subchondral bone by secreting netrin-1, resulting in a reduced pain threshold in an osteoarthritis animal model. Therefore, we assume that inhibition of osteoclasts can alleviate sensory nerve-mediated pain symptoms.

OBJECTIVE: To investigate whether artesunate inhibits subchondral bone osteoclasts and reduces sensory nerve-mediated pain, providing experimental data for the treatment of osteoarthritis pain using artesunate.

METHODS: C57BL/6J male mice were randomly assigned to a sham operation group, a placebo group and an artesunate group, with 10 mice per group. The mice in the sham operation group were only subjected to right knee capsulotomy with no damage to the other structures. Moreover, there was no intervention after operation. In the other two groups, the mice received an anterior cruciate ligament transection of the right knee to establish the osteoarthritis model, followed by treatment with artesunate (artesunate group, 100 mg/kg per day) or equivalent volume of 5% NaHCO₃ (placebo group) via intraperitoneal injection. Fourteen days after surgery, the footprint trial was performed, and the levels of tartrate-resistant acid phosphatase 5b (TRAcP5b), cathepsin K and carboxy-terminal telopeptide of type I collagen (CTX-I) in the peripheral blood were detected using ELISA. The knee joint specimens of each group were subjected to Safranin O-Fast Green staining, histological scoring, tartrate-resistant acid phosphatase (TRAP) staining and immunohistochemical staining with netrin-1 and calcitonin gene-related peptide (CGRP).

RESULTS AND CONCLUSION: The percentage of ipsilateral contact area of the right hindpaw in the footprint trial was significantly higher in the sham operation group and artesunate group than the placebo group (P < 0.05), but there was no significant difference between artesunate group and sham operation group (P > 0.05). No significant differences were observed in the serum levels of TRAcP5b, cathepsin K and CTX-I between the groups (P > 0.05). Based on the Safranin O-Fast Green staining, the cartilage histology score was significantly lower in the sham operation group and the artesunate group than the placebo group (P < 0.05), but there was no significant difference between artesunate group and sham operation group (P > 0.05). TRAP staining indicated that compared with the placebo group, the Trap⁺ osteoclasts were significantly lower in the sham operation group and the artesunate group (P < 0.05), but no significant difference was found between artesunate group and sham operation group (P > 0.05). Compared with the placebo group, the netrin-1⁺ and CGRP⁺ sensory nerves in the subchondral bone were significantly decreased in the sham operation group and the artesunate group (P < 0.05), but the two indices had no significant differences between artesunate group and sham operation group (P > 0.05). Our findings from this study indicate that artesunate improves sensory nerve-mediated pain by inhibiting netrin-1 secreted by subchondral bone osteoclasts, and has therapeutic potential to alleviate osteoarthritis pain.

Key words:

osteoarthritis, artesunate, osteoclast, netrin-1, subchondral bone, pain, calcitonin gene-related peptide

CLC Number:

Shalitanati•Wuermanbieke, Li Yicheng, Ren Jiangdong, Ma Hairong, Mu Wenbo, Cao Li. Artesunate relieves subchondral bone osteoclast-mediated osteoarthritis pain[J]. Chinese Journal of Tissue Engineering Research, 2020, 24(17): 2636-2641.

Figures/Tables 6

References

[1] World Health Organization. Chronic Rheumatic Conditions. Available at: http://www.who.int/chp/topics/rheumatic/en/ (accessed 5 September 2018).
[2] 邱贵兴,裴福兴,唐佩福,等.骨科常见疼痛管理临床实践指南(2018版)[J].中华骨与关节外科杂志, 2019, 12(3):161-167.
[3] O'NEIL CK, HANLON JT, MARCUM ZA. Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. Am J Geriatr Pharmacother. 2012;10(6): 331-342.
[4] NELSON AE, ALLEN KD, GOLIGHTLY YM, et al. A systematic review of recommendations and guidelines for the management of osteoarthritis: The chronic osteoarthritis management initiative of the U.S. bone and joint initiative. Semin Arthritis Rheum. 2014;43(6):701-712.
[5] BANNURU RR, NATOV NS, OBADAN IE, et al. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum. 2009;61(12):1704-1711.
[6] SHETH U, SIMUNOVIC N, KLEIN G, et al. Efficacy of autologous platelet-rich plasma use for orthopaedic indications: a meta-analysis. J Bone Joint Surg Am. 2012;94(4):298-307.
[7] CORBETT MS, RICE SJ, MADURASINGHE V, et al. Acupuncture and other physical treatments for the relief of pain due to osteoarthritis of the knee: network meta-analysis. Osteoarthritis Cartilage. 2013;21(9): 1290-1298.
[8] WALLER B, OGONOWSKA-SLODOWNIK A, VITOR M, et al. Effect of therapeutic aquatic exercise on symptoms and function associated with lower limb osteoarthritis: systematic review with meta-analysis. Phys Ther. 2014;94(10):1383-1395.
[9] ZENG C, LI H, YANG T, et al. Electrical stimulation for pain relief in knee osteoarthritis: systematic review and network meta-analysis. Osteoarthritis Cartilage. 2015;23(2):189-202.
[10] 袁义,吴立东,章海均,等.射频热凝术治疗中老年人膝骨性关节炎顽固性疼痛的疗效观察[J].中华老年医学杂志, 2012, 31(12):1097-1099.
[11] KONGTHARVONSKUL J, ANOTHAISINTAWEE T, MCEVOY M, et al. Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. Eur J Med Res. 2015;20:24.
[12] BURR DB, GALLANT MA. Bone remodelling in osteoarthritis. Nat Rev Rheumatol. 2012;8(11):665-673.
[13] ZHEN G, WEN C, JIA X, et al. Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med. 2013;19(6):704-712.
[14] NWOSU LN, ALLEN M, WYATT L, et al. Pain prediction by serum biomarkers of bone turnover in people with knee osteoarthritis: an observational study of TRAcP5b and cathepsin K in OA. Osteoarthritis Cartilage. 2017;25(6):858-865.
[15] STRASSLE BW, MARK L, LEVENTHAL L, et al. Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease. Osteoarthritis Cartilage. 2010;18(10): 1319-1328.
[16] ZHU S, ZHU J, ZHEN G, et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J Clin Invest. 2019;129(3): 1076-1093.
[17] LIU Z, ZHANG J, LI S, et al. Artesunate Inhibits Renal Ischemia Reperfusion-Stimulated Lung Inflammation in Rats by Activating HO-1 Pathway. Inflammation. 2018;41(1):114-121.
[18] LU H, WANG B, CUI N, et al. Artesunate suppresses oxidative and inflammatory processes by activating Nrf2 and ROS‑dependent p38 MAPK and protects against cerebral ischemia‑reperfusion injury. Mol Med Rep. 2018;17(5):6639-6646.
[19] WEI CM, LIU Q, SONG FM, et al. Artesunate inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro and prevents LPS-induced bone loss in vivo. J Cell Physiol. 2018;233(1):476-485.
[20] GLASSON SS, CHAMBERS MG, VAN DEN BERG WB, et al. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage. 2010;18 Suppl 3:S17-23.
[21] 吕岩,程建国,樊碧发,等. ICD-11慢性疼痛分类中文编译版[J].中国疼痛医学杂志, 2018, 24(11):801-805.
[22] HUNTER DJ, MCDOUGALL JJ, KEEFE FJ. The symptoms of osteoarthritis and the genesis of pain. Med Clin North Am. 2009;93(1): 83-100.
[23] ARENDT-NIELSEN L, NIE H, LAURSEN MB, et al. Sensitization in patients with painful knee osteoarthritis. Pain. 2010;149(3):573-581.
[24] YUSUF E, KORTEKAAS MC, WATT I, et al. Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Ann Rheum Dis. 2011;70(1):60-67.
[25] KWOH CK. Clinical relevance of bone marrow lesions in OA. Nat Rev Rheumatol. 2013;9(1):7-8.
[26] LASLETT LL, DORÉ DA, QUINN SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis. 2012;71(8):1322-1328.
[27] XU L, NWOSU LN, BURSTON JJ, et al. The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis Cartilage. 2016;24(9):1587-1595.
[28] CUI Z, CRANE J, XIE H, et al. Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Ann Rheum Dis. 2016;75(9):1714-1721.
[29] PARFITT AM, DREZNER MK, GLORIEUX FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2(6):595-610.
[30] ZENG X, ZHANG Y, WANG S, et al. Artesunate suppresses RANKL-induced osteoclastogenesis through inhibition of PLCγ1-Ca2+-NFATc1 signaling pathway and prevents ovariectomy-induced bone loss. Biochem Pharmacol. 2017;124:57-68.
[31] JI B, ZHANG Z, GUO W, et al. Isoliquiritigenin blunts osteoarthritis by inhibition of bone resorption and angiogenesis in subchondral bone. Sci Rep. 2018;8(1):1721.
[32] HALLEEN JM. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res. 2003;23(2A): 1027-1029.
[33] BONE HG, DEMPSTER DW, EISMAN JA, et al. Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int. 2015; 26(11):2721.
[34] BIVER E. Use of bone turnover markers in clinical practice. Curr Opin Endocrinol Diabetes Obes. 2012;19(6):468-473.
[35] XI J, LI Q, LUO X, et al. Celastrol inhibits glucocorticoid‑induced osteoporosis in rat via the PI3K/AKT and Wnt signaling pathways. Mol Med Rep. 2018;18(5):4753-4759.
[36] CHEN X, ZHI X, PAN P, et al. Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis. FASEB J. 2017;31(11):4855-4865.
[37] JIMENEZ-ANDRADE JM, MANTYH WG, BLOOM AP, et al. Bone cancer pain. Ann N Y Acad Sci. 2010;1198:173-181.
[38] MEDIERO A, RAMKHELAWON B, PEREZ-ASO M, et al. Netrin-1 is a critical autocrine/paracrine factor for osteoclast differentiation. J Bone Miner Res. 2015;30(5):837-854.
[39] ZHAO C, LIU Q, WANG K. Artesunate attenuates ACLT-induced osteoarthritis by suppressing osteoclastogenesis and aberrant angiogenesis. Biomed Pharmacother. 2017;96:410-416.